Noveltea is a premium alcoholic tea brand launched in Fenwick in April 2017. The company's products are vegan, gluten-free and low in sugar, and manufactured in minimalistic & up-cyclable lifestyle packaging. Thanks to its low-Alcohol by volume (ABV) portfolio, the brand has sold 350,000 bottles since its launch in 2017. The company experienced more than £100,000 worth of sales in April 2020 despite COVID-19 due to smart e-commerce channel utilisation. In 2020, the size of the global alcoholic drinks market is $1.587 trillion and is forecasted to grow by 3.5% (CAGR) over the next three years. The brand aims to become a major contender in this segment and grow its business. The company use the investment to focus on its core markets in the UK, Germany, and China, and enter the USA by 2020.
days to go:
Expired
investment:
£558,845
Mr Lee’s Pure Foods is an innovative food/tech company creating award-winning premium healthy noodles-in-a-cup and will be launching its new instant Congee Asian rice porridge. All products are certified low sugar, gluten-free, low on calories, Vegan options and 100% recyclable and compostable packaging. The global instant noodle market is expected to reach $57.5 billion by 2024 which the brand aims to capitalise on and establish itself in as the market leader. Mr Lee's has won 50+ global awards and nominations including Grocer Gold Exporter of the Year, Great British Entrepreneur winner, and The Sunday Times Maserati 100 winner. Noted publisher Penguin Random House has published Mr Lee’s 100 Noodle Recipe cookbook which has been met with critical acclaim worldwide. With the investment, the company will invest 25% of it in marketing initiatives and entering into the US market, 10% in product development, 20% in working capital for food production during scale-up, 5% in upgrading its Hot Noodle Kiosk and vending machine facilities, and 40% in global group operating and personnel costs runway for commercial functions and scale-up activities within Australia, the UK, and the USA.
days to go:
Expired
investment:
£1,835,892
Scribestar's Software-as-a-Service (SaaS) platform digitises and automates the documentation and compliance processes required for raising capital on stock markets such as IPOs, bonds etc. The platform intends to provide users with structured data format documents that can be machine-read and monetised. Scribestar aims to become a contender in the $22 billion Regulatory/Legal Technology markets. It argues that it is already active in the UK and has witnessed over 50 transactions on its system. It is also a part of the London Stock Exchange Issuer Services and CMS equIP with 4 years of verifiable commercial use and over £13 million received as investments. Scribestar asserts that its services are being regularly used by three law firms in the UK with more showing interest in its capability to function as a remote tool to manage the compliance documentation process. The company will use the investment to start its expansion in the US and other markets targeting law firms and deliver successful trials with stock exchanges.
days to go:
Expired
investment:
£864,009
Coconuts Organic is a company that produces plant-based ice creams. Coconuts Organic asserts that it is one of only two mainstream organic plant-based ice cream brands in the UK. The company aims to tap into the fast-growing global trend of healthier eating and sustainable food. Coconuts Organic has won seven Great Taste Awards and became the fastest-growing 'Wellness Ice Cream' brand in the UK according to a May 2020 Nielsen report. Its products are stocked in major retail chains like M&S and Ocado. The company will use the investment to grow its sales and marketing team, increase its eCommerce business, scale its operations, and invest in marketing activity that will create consumer demand.
days to go:
Expired
investment:
£327,979
Crosspay is a company that aims to make remittance simpler and cheaper. The company built its proprietary system in 2017 to bolster international transfers at a fraction of the money charged by traditional Over-The-Counter (OTC) services. It has since powered over 50,000 transactions across 50 countries with a cumulative value of approx £32,350,000. The company aspires to become the segment leader in the more than $200 billion global remittance market. Crosspay was rated 'Excellent' on Trustpilot. It also created white-labelled apps for charities and churches to host content, broadcast live and receive donations simultaneously, irrespective of location. The company has been invited to partner on an Innovate UK project. It will use the investment to grow its business across different verticals.
days to go:
Expired
investment:
£212,581
ByRuby is a food delivery company. It sources produce from local ethical suppliers, prepares meals in small batches using the raw produce, freezes the meal to preserve the taste, and delivers it nationwide. ByRuby argues that the UK ready meal sales market is worth £12 billion in 2020. The company witnessed sales up to 200% online in March 2020. ByRuby asserts that it uses only British free-range or organic meat & sustainably sourced fish from British waters. The company won the 2018 Women's Health Food Award. Its products are stocked in 26 retail stores. ByRuby has been mentioned by publications such as Daily Mail, Daily Telegraph, and Metro. It will use 50% of the investment for marketing, 26% to grow its kitchen team, 17% to upgrade its kitchen and 7% for new product development.
days to go:
Expired
investment:
£288,243
Sendit.Money is a remittance entity. It argues that individuals sending or receiving money in emerging markets can face insecure processes, slow transaction times and incur high costs. Sendit.Money asserts that this is because non-fiat currencies are changed multiple times before they are received. The company aims to change this. Its prototype application for African markets was received amidst positive feedback. It is now building a cost-effective mobile wallet providing a secure and inexpensive way to send and receive money that also allows users to compare transfer fees of different remittance agents in real-time. Sendit.Money was shortlisted as Best Global start-up at the 2020 Wales Startup Awards. The company will build and launch its Most Valuable Product (MVP) in Q3 of 2021. It will also use the funding to begin work with an authorised entity to become an approved representative.
days to go:
Expired
investment:
£182,732
Wirex is a UK financial technology company that aims to bring crypto & fiat currencies together on one simple payments portal. The company is building a platform where buying, holding, saving and spending any digital and traditional currency is quick, easy and accessible. The Wirex app supports 12 fiat and 10 crypto currencies, operates in 130 countries, and has more than 3.1 million registered users. Wirex launched the first Visa crypto-enabled payments card in the world. It has a £3 billion cumulative transaction volume and plans to expand to the USA by end-2020. Wirex will use the investment to allow millions of its users to own a share of the brand.
days to go:
Expired
investment:
£3,703,120
C-Major is a medical technology company. It asserts that over 2 million people suffer a Needle Stick Injury (NSI) every year and are at risk of contracting blood-borne viruses such as Hepatitis and HIV. It aspires to resolve this crisis by bringing to market its patented medical device, Controlled Helical Retraction Device, to prevent NSIs. The company argues that the device contains a ‘Helical Track’ mechanism for controlled acceleration of the needle during retraction as well as a ‘Sealed Port’ to minimise any blood splatter. C-Major endeavours to disrupt the $5.5 billion safety syringe market with its product. It is backed by the UK 'Innovation Seed' fund. C-Major will use the investment to complete the final design of its product for manufacture and assembly ahead of a Series A funding round in 2021.
days to go:
Expired
investment:
£211,595
Anastasis Biotec (AB) is a company that is developing a human protein-based product, Syntana-4 (S-4), that inhibits Cancer Stem Cells (CSC) - the growth engine of cancer. The global cancer drug market was at ~$200 billion in 2019. S-4 will initially target use for patients with relapsed prostate cancer which caused 3.8% of global cancer deaths in 2018. The company asserts that S-4 will have low manufacturing costs, making it affordable, enabling ‘mass-market’ sales. AB has raised £450,000 in equity convertible loans and grants in 2019 & 2020, including an Innovate-UK award. It is also aiming to progress S-4 further in collaboration with the University of Chicago’s cancer stem cell therapeutics Research and development (R&D) program. The company will use the investment to complete lab-testing before starting clinical trials.
days to go:
Expired
investment:
£270,543
